Nitric oxide (NO) may exhibit proinflammatory features. *NO synthase type 2 (NOS2) is overexpressed and 'NO overproduced in rodent models of induced inflammation. Blockage of 'NO production by administration of NOS inhibitors prevents or reduces various types of induced inflammation in mice and rats. We have shown that autoimmune MRL-lpr/1pr mice overexpress NOS2 and overproduce 'NO in an age-dependent fashion that parallels expression of arthritis, glomerulonephritis, and vasculitis. Blocking 'NO production by oral administration of the NOS inhibitor M\-monomethyl-L-arginine reduced the arthritis, glomerulonephritis, and vasculitis, but it did not modify serum anti-DNA antibody levels or glomerular deposition of immune complexes. When mice with genetically disrupted NOS2 were backcrossed to MRL-lpr/1pr mice, the resultant (-/-) mice expressed no NOS2 and produced no 'NO, the wild-type (+/+) mice overexpressed NOS2 and overproduced 'NO (in comparison to normal, control mice), and the heterozygous (+/-) mice expressed and produced intermediate levels. Nephritis and arthritis in the (-/-) mice were comparable to that in MRL-lpr/lpr mice, but vasculitis was markedly decreased. Levels of anti-DNA antibodies were comparable in all mice, but lgG rheumatoid factor production was markedly reduced in the (-/-) mice. These results of studies in MRL-lpr/lpr mice with genetically disrupted NOS2 highlight the heterogeneity and complexity of the role of NOS2 and 'NO in inflammation.
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Abbreviations used: COX, cyclooxygenase; eNOS or NOS3, endothelial cell nitric oxide synthase; EPR, electron paramagnetic resonance; Hb, hemoglobin; IFN, interferon; IL, interleukin; iNOS or NOS2, inducible nitric oxide synthase; V-IRE, IFN-y response element; IRE-BP, iron response element-binding protein; ISRE, IFN-a stimulatable response element; KO, knockout; LPS, lipopolysaccharide; Mb, myoglobin; NMMA, M-monomethyl-L-arginine; nNOS or NOS1, neural nitric oxide synthase; 'NO, nitric oxide; NOHb, nitrosylhemoglobin; NOS, nitric oxide synthase; OA, osteoarthritis; OONO, peroxynitrite; 02-. superoxide anion radical; RA, rheumatoid arthritis; RF, rheumatoid factor; ROS, reactive oxygen species; SOD, superoxide dismutase; TfR, transferrin receptor; TGF-,B, transforming growth factor P; TNF, tumor necrosis factor. combined actions of these mediators (along with certain inherent and induced anti-inflammatory mediators) contribute to the eventual pathology-accumulation of inflammatory cells, modification of synovial vascular cells, proliferation of synovial fibroblasts, disruption of the general synovial architecture, and destruction of cartilage and bone. NO, 02,-and OONO-appear to be central to the inflammatory process. Antioxidant enzymes such as catalase, superoxide dismutase (SOD), and glutathione peroxidase may be critical as endogenous defenses against inflammation. Various cells in the joint may participate in the inflammation. These include mononuclear phagocytes and chondrocytes.
NO and Nitric Oxide Synthase
The simple gas NO has multiple important physiologic and pathologic functions [(8-10) for reviews]. These include roles in (to mention only a few) host resistance to tumors and microbes, regulation of blood pressure and vascular tone, neurotransmission, learning, and neurotoxicity, carcinogenesis, and control of cellular growth and differentiation (11, 12) . In the presence of oxygen, NO rapidly (seconds) is converted to nitrite and nitrate, substances that are generally not bioactive [(13) (15, 16, (23) (24) (25) . Some have shown human monocyte 'NO production, but levels have been low when compared to murine mononuclear phagocytes [ (22, (26) (27) (28) for review]. In a study of normal human monocytes and peritoneal macrophages, we showed that these cells can produce NOS2 mRNA, protein, and 'NO, but levels were much less than that of mouse macrophages (29) . We examined a large array of culture conditions and cytokines. IFN-y and LPS showed only slight activity. Human alveolar macrophages have NOS2 antigen (30, 31) , and patients with tuberculosis have increased numbers of alveolar macrophages that express NOS2 antigen (32) . Humans can be induced to make high levels of *NO in vivo via an NOS mechanism (33) , but the cells responsible for *NO production in vivo are not known. We 
NO and Inflammation
'NO has many actions appropriate for a proinflammatory agent. It is made by numerous cell types in sites of inflammation, and it increases blood flow and vascular permeability. *NO has cell/tissue destructive abilities, and it can induce cyclooxygenase (COX), cause pain, destroy certain protease inhibitors, and enhance production of IL-1 and TNF, and NADPH oxidase activity in myeloid cells (11, 36) . 'NO production may result from the actions of several substances including cytokines, immune complexes, and bacterial products ( Figure 1 ). Because 02--may interact with 'NO to produce OONO-, coincident production of 'NO and O2f-sets the stage for a severe inflammatory state.
In the joint, several cell types may produce 'NO-macrophages, chondrocytes, endothelial cells, and possibly others.
Macrophages and chondrocytes are the most likely contributors. Human articular chondrocytes produce relatively high levels of 'NO, and cytokines can augment this production (15, 37, 38) . Synovial fibroblasts in patients with arthritis also express NOS2 and produce 'NO (39) . Because several paths might lead to increased 'NO production, blocking only one pathway (e.g., blocking an IFN alone) might not fully blunt 'NO production, since alternate paths could compensate ( Figure 1 ).
Researchers have noted that in addition to proinflammatory effects, 'NO may also be anti-inflammatory. The double-edged sword phenomenon in *NO biology thus applies to inflammation as well as to other areas in *NO biology (8, 40) . *NO modifies adhesiveness and chemotaxis of polymorphonuclear neutrophils and monocytes (41, 42) , inhibits platelet aggregation and secretion (43) , and inhibits cell proliferation [including lymphocytes (8) ].
Arachidonic acid metabolites play important roles in inflammation, and COX inhibitors are drugs useful in the management of inflammatory disease (44) . There is significant cross-talk between *NO and COX. Eicosanoids can reduce NOS2 expression and 'NO production (45) (46) (47) , and *NO modulates prostaglandin E2 formation (48) . Stimuli that enhance NOS2 and *NO formation also may induce COX2 expression, but the time course for induction differs (49) (50) (51) . Arginine analogues such as NG_ monomethyl-L-arginine (NMMA) may be anti-inflammatory by inhibiting both COX2 and NOS (52) . Furthermore, aspirin, in high doses, inhibits both cyclooxygenase and NOS2 (53) .
'NO is important in animal models of arthritis that mimic human RA. These include adjuvant arthritis, collageninduced arthritis, and spontaneous arthritis in MRL mice [(36,38,54) (58) (59) (60) . Kaur and Halliwell (61) showed increased levels of nitrotyrosine (a product resulting from OONO-action) in serum and synovial fluid from arthritis patients (61 (39) . Ueki and co-workers (63) showed that RA patients have higher serum 'NO than do osteoarthritis (OA) patients, that RA synovial fluid 'NO was much higher than serum 'NO, and that serum *NO levels correlated significantly with clinical parameters of disease activity (duration of morning stiffness, number of swollen and tender joints, and serum levels of C-reactive protein, TNF, and IL-6). We had earlier noted comparable associations (35 (69, 70) .
NO, OONO-, Inflammation, and Arthritis
We noted earlier that the macrophages of MRL-/pr/lpr mice are activated in various ways, including enhanced ROS generation (67) . We hypothesized that they might also overproduce 'NO (66) , and we demonstrated that they spontaneously excrete 5 to 10 times more urinary nitrite/nitrate (stable oxidation products of *NO) than normal mice. They have enhanced expression of NOS2 mRNA and protein in macrophages, liver, kidney, and spleen. NOS2 maps to mouse chromosome 1 1 (corresponding to human 17p2 1); this location is different from sites previously determined to be linked to disease susceptibility [chromosome 19 (fas), 7 (73) . We measured NOHb in whole blood. MRL-lpr/lpr mice had statistically significant elevated levels of NOHb in blood (74) . This increased with age and paralleled the course of 'NO overproduction. We also examined the kidneys using EPR and found that MRL kidneys have a nitrosyl nonheme iron protein signal, as well as some NOHb (probably from blood trapped in the kidney). The nitrosyl nonheme iron protein at g= 2.04 may be an iron-sulfur cluster protein such as one of the mitochondrial electron transport enzymes.
Our studies showed that kidneys from MRL mice have an increase in the amount of nitrotyrosine-containing proteins. Nitrotyrosine is formed as a consequence of action of OONO-on tyrosine in proteins, and thus may serve as a marker of 'NO and OONO-action in tissues (75) (76) (77) . On immunoblots using specific antinitrotyrosine antibody, extracts from kidneys from normal mice were essentially negative, whereas those from MRL mice had two major bands of immunoreactivity (A,= 60,000 and 48,000) and three minor bands (78) . Reactivity was eliminated by omitting the primary antibody or by coincubating the primary antibody reaction mixture with 10 mM nitrotyrosine. The identity of the nitrated proteins in the tissues from the diseased kidneys is presently unknown. 'NO and OONO-can react with numerous different proteins, and these reactions can alter functions of some (9, 10) . In an attempt to identify one of the target proteins for 'NO and OONO-, we measured catalase activity in the mouse kidneys. Catalase (86) .
The (+/+) mice excreted large amounts of nitrite/nitrate, confirming our prior observations (66) . The (+/-) mice excreted intermediate levels, whereas (-/-) mice excreted very low levels of nitrite/nitrate (comparable to those of normal BALB/c mice). Nitrite/nitrate levels in sera from 20-week-old animals paralleled the urinary measures, with very low levels in the (-/-) mice, high levels in the (+/+) mice, and intermediate levels in the (+/-) mice. Levels of urinary and serum nitrite/nitrate in (+/+) or (+/-) mice were significantly higher than those in the (-/-) mice (86) .
To assess in vitro 'NO production by cells from mice of the three groups, we cultured peritoneal macrophages without additives and with IFN-,y (50 U/ml) and LPS (10 ng/ml). Nitrite/nitrate levels were significantly lower in the tissue culture supernatants of macrophages from the (-/-) mice than (+/+) mice or the (+/-) mice, both at baseline and following stimulation. Similarly, NOS2 enzyme activity, as measured by the conversion of L-arginine to L-citrulline, was significantly less in the cells from (-/-) mice than those from (+/-) or (+/+) mice. NOS activities were reduced by more than 90% by inclusion of 2 mM NMMA in the reaction mixtures. These studies confirm lack of detectable NOS activity in (-/-) mice (86) .
Immunoblots were performed on protein extracts from spleens, kidneys, liver, and peritoneal macrophages from the mice using an anti-NOS2 antibody. The macrophage cell line J774 (no treatment or treated with LPS/IFN-y) served as control. As noted earlier, tissue from BALB/c mice had no NOS2. There was minimal or no detectable NOS2 in the splenic, kidney and macrophage protein extracts from (-/-) mice. Extracts from (+/+)and (+/-) mice contained NOS2 protein, with those of the (+/-) mice having approximately half the amount of the (+/+) mice (86) .
Based on the effect of in vivo administration of NMMA on renal disease and arthritis in MRL-Ipr/ipr mice (66) (86) .
Infiltrates of lymphocytes and perivascular collection of lymphocytes occur in the kidneys of all /pr mice regardless of genetic background (64, 87) ; true mediumto-large vessel vasculitis is found, however, only in MRL-lpr/ipr mice (87) (88) (89) . Mononuclear cell infiltrates were present in the kidneys of all mice in this study. However, in contrast to glomerulonephritis and arthritis, there was a significant difference in the presence and severity of medium-to-large vessel vasculitis, depending on NOS2 genotype. Indeed, 4 of 6 (+/+) mice had prominent vasculitis ofmedium-to-large vessels in the kidney, whereas only 1 of 9 of the (+/-) mice and 0 of 9 of (-/-) mice had mediumto-large vessel vasculitis. The incidence of vasculitis in the (+/+) mice was similar to that in 20-week-old female MRL-lpr/lpr mice (80%). The difference in the occurrence of vasculitis between the (+/+) mice and the (-/-) mice was statistically significant. Pathologic examination of the brain, liver, lymph nodes, spleen, and lung revealed similar mild lymphocytic infiltration in all three groups (86) .
MRL-lpr/lpr mice are notable for autoantibody production (64, 87 eDegree of positivity, with 0 being none and 4+ being the maximum. 'Not determined.
inhibitor, blocking all three isoforms of the NOS enzymes (92) . Inhibiting all NOS isoforms (and hence potentially all NO production) with NMMA may be more effective in disease prevention than genetically disrupting only NOS2. Alternative inflammatory pathways may not be active when NO production is acutely blocked by NMMA; however, these pathways might become active over time when NOS2 is genetically disrupted and absent the entire life of the animal.
Conclusions
Thus, MRL-/pr/lpr mice spontaneously overexpress NOS2 and overproduce NO in parallel with the development of autoimmunity and inflammation. Inhibiting 'NO production in vivo by oral administration of NMMA from 10 to 20 weeks of age prevents development of glomerulonephritis, arthritis, and vasculitis. This indicates that 'NO is important in the pathogenesis of glomerulonephritis, arthritis, and vasculitis in these mice. However, in MRL-/pr/lpr mice with genetically disrupted NOS2, arthritis and glomerulonephritis are unaltered, whereas vasculitis is reduced. These studies highlight the heterogeneity and complexity of the roles of NOS2 and 'NO in inflammation in MRL-Ipr/Ipr mice.
